Nucleo Research, Inc.

About Nucleo Research, Inc.

Nucleo provides automated AI technology to streamline clinical workflows in oncology care using CT scan analysis. The platform offers automatic quantification of body composition, precise tumor lesion sizing, and lesion classification based on RECIST criteria. This automation accelerates analysis compared to manual segmentation, improving consistency in diagnostic imaging review.

Nucleo provides automated AI technology to streamline clinical workflows in oncology care using CT scan analysis. The platform offers automatic quantification of body composition, precise tumor lesion sizing, and lesion classification based on RECIST criteria. This automation accelerates analysis compared to manual segmentation, improving consistency in diagnostic imaging review.

What does Nucleo Research, Inc. do?

Nucleo provides automated AI technology to streamline clinical workflows in oncology care using CT scan analysis. The platform offers automatic quantification of body composition, precise tumor lesion sizing, and lesion classification based on RECIST criteria. This automation accelerates analysis compared to manual segmentation, improving consistency in diagnostic imaging review.

Employees
3 employees
Investors
Lombardstreet

Nucleo Research, Inc.

8
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Nucleo provides automated AI technology to streamline clinical workflows in oncology care using CT scan analysis. The platform offers automatic quantification of body composition, precise tumor lesion sizing, and lesion classification based on RECIST criteria. This automation accelerates analysis compared to manual segmentation, improving consistency in diagnostic imaging review.

nucleoresearch.com300+

Funding

Backed by

Lombardstreet

Team (<5)

No team information available.

Company Description

Nucleo provides automated AI technology to streamline clinical workflows in oncology care using CT scan analysis. The platform offers automatic quantification of body composition, precise tumor lesion sizing, and lesion classification based on RECIST criteria. This automation accelerates analysis compared to manual segmentation, improving consistency in diagnostic imaging review.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.